(Q35132177)

6 August 2017

1 reference

title

Guidelines and methodological reviews concerning drug abuse liability assessment (English)

1 reference

6 August 2017

1 reference

Robert L Balster

1

1 reference

PubMed ID

12759195

6 August 2017

George E Bigelow

series ordinal

2

1 reference

6 August 2017

1 June 2003

1 reference

Drug and Alcohol Dependence

6 August 2017

1 reference

6 August 2017

70

1 reference

6 August 2017

S13-40

1 reference

6 August 2017

3 Suppl

1 reference

Regulation and abuse liability testing of medicines in Europe beyond 1992.

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Postmarketing surveillance for drug abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Self-administration of barbiturates and benzodiazepines: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Principles of drug abuse liability assessment in laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Abuse potential evaluation of inhalants

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Abuse potential of buspirone and related drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Drug abuse potential evaluation in animals

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Review of self-administration

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Δ9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Human drug abuse liability assessment: opioids and analgesics

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Animal models for assessing drugs of abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Assessing abuse liability in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Anxiolytics and sedative/hypnotics dependence.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Self-administration of psychoactive substances by the monkey

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Preference procedures for testing the abuse liability of drugs in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Testing the abuse liability of anxiolytic and hypnotic drugs in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Abuse liability assessment of anxiolytics/ hypnotics: rationale and laboratory lore

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Pharmacokinetic considerations in abuse liability evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Utility of subjective-effects measurements in assessing abuse liability of drugs in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Assessment of abuse liability of stimulant drugs in humans: a methodological survey

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Methods for the assessment of abuse liability of psychomotor stimulants and anorectic agents in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Arylalkylamine drugs of abuse: an overview of drug discrimination studies

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Benzodiazepine self-administration in humans and laboratory animals--implications for problems of long-term use and abuse.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Drug self-administration methods in abuse liability evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Drug discrimination studies

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Impact of scheduling on the practice of medicine and biomedical research

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

History of abuse liability testing in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

The evaluation of the abuse liability of drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Abuse liability assessment of neuroprotectants

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Tramadol post-marketing surveillance in health care professionals

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Incorporating the assessment of abuse liability into the drug discovery and development process

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

The Committee on Problems of Drug Dependence: a legacy of the National Academy of Sciences. A historical account

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Protection of participants and experimental design in clinical abuse liability testing

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

GHB: a new and novel drug of abuse

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Drug abstinence effects: opioids

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Drug discrimination methods in human drug abuse liability evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Abuse liability studies of opioid agonist-antagonists in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Performance and physiological measures in abuse liability evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Behavioral pharmacology of zolpidem relative to benzodiazepines: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Drug metabolism and interactions in abuse liability assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Keeping the lid on: a century of drug regulation and control

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

The necessity and utility of abuse liability evaluations in human subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Addictive Drugs and Brain Stimulation Reward

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Substitution and primary dependence studies in animals.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Dependence characteristics and risk assessment of agonist-antagonist analgesics

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

Substitution of psychoactive drugs in pentobarbital-dependent rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0376-8716%2803%2900097-8

7 January 2021

10.1016/S0376-8716(03)00097-8

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12759195